As Jessani et al., 1 point out development of cell and animal models that accurately depict human tumorigenesis remains a major goal of cancer research. Clam cancer offers significant advantages over traditional models for genotoxic and non-genotoxic preclinical analysis of treatments for human cancers with a similar molecular basis. The naturally occurring clam model closely resembles an outbreeding, human clinical population and provides both in vitro and in vivo alternatives to those generated from inbred mouse strains or by intentional exposure to known tumor viruses. Fly and worm in vivo models for adult human somatic cell cancers do not exist because their adult somatic cells do not divide. Clam cancer is the best characterized, naturally occurring malignancy with a known molecular basis remarkably similar to those observed in several unrelated human cancers where both genotoxic and non-genotoxic strategies can restore the function of wild-type p53. To further emphasize this point of view, we here demonstrate a p53-induced, mitochondrial-directed mechanism for promoting apoptosis in the clam cancer model that is similar to one recently identified in mammals. Discerning the molecular basis for naturally occurring diseases in non-traditional models and correlating these with related molecular mechanisms responsible for human diseases is a virtually unexplored aspect of toxico-proteomics and genomics and related drug discovery.
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The soft-shell clam, Mya arenaria, develops a blood cancer at high incidence (≥2%) in nature. In this leukemia-like disease, a highly conserved clam homolog (GenBank Accession #AF253323) for human wild-type p53 protein is rendered non-functional by sequestration in the cytoplasm of leukemic clam hemocytes (LCH). [2] [3] [4] This phenomenon in clams reflects that seen in a group of unrelated human cancers, yields a similar phenotype and results in loss of transcriptional function. 5 In all of these cases, wild type p53 does not initiate transcription of down-stream nuclear genes because it is retained in the cytoplasm. There are multiple mechanisms responsible for cytoplasmic sequestration of p53 in human cancer cells and most of these are poorly understood. 6 In clam cancer as in human glioblastoma and colon carcinoma cells in some patients, wild type p53 is tethered in the cytoplasm by mortalin when this Hsp70 relative is overexpressed. [7] [8] [9] [10] As pointed out by Walker et al., 4 "Non-genotoxic and genotoxic strategies for reactivating p53 function are of high interest because they may lead to promising cancer therapies." This is particularly true when wild type p53 is inactivated. Immunocytochemistry, co-immunoprecipitation and subcellular localization of clam p53 and mortalin proteins before and after treatment with the rhodocyanin dye MKT-077 were assessed for normal (NCH) and leukemic (LCH) clam hemocytes in vivo and in vitro. We showed that clam p53 and mortalin proteins form complexes in the cytoplasm of LCH and not in NCH and that mortalin-based cytoplasmic sequestration of clam p53 is disrupted by MKT-077. 3 In LCH, treatment with the rhodocyanin dye MKT-077 results in translocation of some clam p53 wild type protein from the cytoplasm to the nucleus and ultimately in apoptosis. Competition between clam p53 and MKT-077 for mortalin's p53 binding site (97% conserved with that of human mortalin), provides an explanation for this response after treatment with MKT-077. This treatment results in a reduction of the effective concentration of clam mortalin in LCH. The distribution of clam p53 protein reflects the pattern established by mortalin protein tethers in mouse and human cells. Cytoplasmic sequestration leads to inactivation of p53 family proteins in all of these organisms and is especially common in human neuroblastomas (up to 96% in undifferentiated neuroblastomas), colon carcinomas and glioblastomas. [7] [8] [9] [10] In mammals, reversal of cytoplasmic sequestration of wildtype p53 protein can be achieved by a variety of means, all of which result in translocation of p53 to the nucleus. Because these are wild-type proteins, their renewed presence in the nucleus "reactivates" them to direct p53-related nuclear transcriptional activities, usually resulting in apoptosis of the cancer cells. In all cases so far observed, reversal of cytoplasmic sequestration and resultant nuclear function of p53 protein require either a reduction in the amount or availability of the cytoplasmic anchoring protein or in DNA damage-dependent overproduction and activation of p53 protein.
Treatment with MKT

Genotoxic Stress Reactivates Wild Type p53 Transcriptional Activity and Leads to Apoptosis by Overcoming MortalinBased Cytoplasmic Sequestration
We have demonstrated that genotoxic stress promotes de novo transcription of wild type p53, translocation of p53 to the nucleus and apoptosis of LCH. 4 In untreated LCH, p53 is complexed throughout the cytoplasm with an overexpressed clam homolog for human mortalin. In vitro treatment with etoposide only and in vivo treatment with either etoposide or mitoxantrone induces DNA damage, elevates expression of p53 600-fold, promotes nuclear translocation of p53 and results in apoptosis of LCH. Pretreatment with the nuclear pore blocker wheat germ agglutinin (WGA) followed by etoposide treatment induces DNA damage and elevates p53 expression 893-fold, but does not overcome cytoplasmic sequestration of p53 or induce apoptosis. The apoptotic outcome was prevented by action of the nuclear pore blocker, experimentally excluding newly produced p53 protein from entering the nucleus. LCH have an intact p53 pathway and maintenance of this tumor phenotype requires nuclear absence of p53 resulting from its localization in the cytoplasm of LCH. The effects of topoisomerase II poisons may result as mortalin-based cytoplasmic tethering is overwhelmed by de novo expression of clam p53 protein following DNA-damage induced by genotoxic stress. We point out that while cytoplasmic sequestration of p53 occurs in a variety of human cancers, no one has previously linked treatment with these topoisomerase II poisons to reversal of mortalin-based cytoplasmic sequestration and apoptotic death of cancer cells in any organism. The latter are novel data on p53/mortalin interactions provided by the clam cancer model and have not been observed to date for human cancers. Human colon carcinoma cell lines (HCT116 and RKO) do demonstrate that overexpression of wild-type p53 is facilitated in etoposide-induced death of cancer cells, but it is unclear if mortalin is involved in this case. 11 An outstanding question resulting from our previous studies is: Does non-transcriptional induction of apoptosis occur in LCH through mitochondrially directed p53?
Wild type p53 protein is upregulated in LCH following treatment with the topoisomerase II poison etoposide. This de novo p53 protein is blocked from entering the nucleus, is directed to mitochondria and promotes non-transcriptional induction of apoptosis
In mammals, p53 is activated and/or stabilized by phosphorylation during G 1 /S-phase traverse or as a result of DNA damage. It then enters the nucleus, binds to DNA as a tetramer and interacts with components of the basal transcriptional machinery to upregulate p53 regulatory genes, DNA editing and repair genes and/or apoptosis promoting genes. In cells with severely damaged DNA, apoptosis usually results, while cells with repairable DNA continue through the cell cycle.
Recent studies in several laboratories have demonstrated that in addition to its role as a transcription factor, p53 has a direct, nontranscriptional apoptogenic role at the mitochondria in mouse and human cells. [12] [13] [14] [15] Wild type p53 exists as a dimer or oligmer at the mitochondrial membrane and binds via its DNA binding domains with Bcl2 forming an inhibitory complex. Such binding disrupts the anti-apoptotic Bcl2/BAX ratio and results in outer mitochondrial membrane permeability and the release of toxic peptides from the outer compartment of the mitochondrion resulting in apoptosis. 14 The detailed mechanisms of Bcl2/p53 induced apoptosis remain unclear. We have demonstrated that pre-treatment with the nuclear pore blocker WGA followed by treatment with 3.5 μm MKT-077 results in translocation of p53 to the mitochondria and subsequent apoptosis (Fig. 1) . Mortalin levels were overexpressed in LCH, but treatment with MKT did not result in further elevation of mortalin levels. These results suggest that mortalin-based cytoplasmic sequestration of p53 in leukemic clam hemocytes can be reversed using MKT-077 and will result either in transcription-based apoptosis (following nuclear translocation of p53) when the nucleus is accessible or non-transcription-based apoptosis (following mitochondrial translocation of p53) when nuclear access is blocked. Figure 1 . Mitochondrial translocation of clam p53. Cytoplasmic, nuclear and mitochondrial protein extracts from leukemic clam hemocytes treated with WGA only MKT-077 only or pre-treated with WGA followed by treatment with MKT-077 for six hours. WGA, wheat germ agglutinin (nuclear pore blocker).
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Naturally-Occurring Molluscan Cancer Models in Preclinical Studies of Treatments for Human Cancers
Reliable animal models are critical for evaluating novel tumor therapies and in pre-clinical analysis of the efficacy of novel therapeutic drugs. 16 Historically, tumor models have been generated by inoculating inbred animals with tumor cells from the same genetic strain. Many of these transplants are not reliable as predictors for human clinical trials because they do not adequately model human malignancies. More recent transgenic animal models where malignancies develop spontaneously and progress through known pre-malignant and malignant stages are closer mimics of human malignancies. However, the clam leukemia model is a naturally occurring disease that is generated without any experimental induction that might lead to anomalous tumor progression.
A number of recent studies use proteomic and/or genomic analyses to generate gene profiles characteristic of certain cancers (e.g., breast and colorectal cancer). [17] [18] [19] [20] [21] [22] These studies have emphasized the importance of mutant versions of a variety of relevant genes and have provided elegant means for assessing interrelationships between these defective genes in particular cancers. The clam cancer model employs a novel approach regarding wild type p53. As Dundas et al., 10 point out, "Loss-of-function p53 mutations are common abnormalities in many tumors, but disruption of wild-type p53 activity by mortalin binding may also be prevalent in colorectal adenocarcinomas." These authors also indicate that the mechanisms responsible for mortalin overexpression are unclear and that several cancer microarray analyses indicate that mortalin is also strongly overexpressed in these cancers as well. The implications of these observations have not been analyzed for any human cancer. Because we can induce clam cancer in otherwise normal clams (unpublished data), we are in a unique position to observe changing profiles of p53 interacting proteins during initiation and progression of this mortalin-based disease.
We usually don't know enough about the molecular biology of marine invertebrates to address molecular mechanisms that generate naturally occurring diseases. Soft shell clam leukemia provides excellent in vivo and in vitro models for human and other animal cancers displaying cytoplasmic sequestration of the p53 tumor suppressor by mortalin. 3, 4 While partial or full-length sequences for p53-like proteins have been identified in the genomes of many invertebrate organisms from sea anemones to cephalochordates, full-length sequences for wild-type p53 proteins are now available for three bivalve molluscs found along the Eastern Coast of the United States (p53 from the soft shell clam Mya and from two species of the mussel Mytilus are 99% identical to each other). 2, 23 Even though molluscs and vertebrates diverged over 500 + MYA, bivalve p53s are the most highly conserved, non-deuterostome proteins available for comparison with human p53, particularly in the transcriptional activation domain (TAD is less than 2% conserved in both fly and worm and greather than 70% conserved in molluscs). [24] [25] [26] [27] Soft shell clam leukemia is simultaneously a good model for the effects of toxic compounds, since as Van Beneden 28 points out, "Bivalves have low monooxygenase activity and as a result, compounds slowly accumulate and tissue burdens can serve as integrative indices of bioavailable contaminants". The EPA has come under increased scrutiny for the use of vertebrate, particularly mammalian, models in bioassessment of environmental hazards. There is increased pressure to develop protocols for evaluating potential hazardous compounds found or released into the aquatic environment. Bivalves are EPA approved for bioassessment and fifteen other bivalve mollusks present phenotypically similar blood diseases resemblng that seen in the soft shell clam (e.g., Mytilus, Crassostrea, Macoma, Cerastroderma, Mercenaria & Venus). These naturally occurring molluscan diseases might also be developed as models where exposure pathways or molecular mechanisms are shared with human diseases. 29 
